Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period

Condition(s) studied

Investigational drug(s) / intervention(s)

Beta-3 agonists (Mirabegron/Myrbetriq): Patients in this arm will receive the medication in pill form following their procedure

Placebo group post rezum: Patients in this arm will receive the placebo pill following their procedure.

Study summary

The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.

Eligibility

Primary outcome measure(s)

• Change in symptom scores — Symptom scores will be taken pre-op at time of consultation and at 1, 2 and 4 week follow-up
  Change in the following symptoms scores IPSS-QOL (higher scores indicate worser outcomes)
• Change in symptom scores — Symptom scores will be taken pre-op at time of consultation and at 1, 2 and 4 week follow-up
  Change in OABSS symptom scores. (higher scores indicate worse outcomes)

Trial sites (1)

More University of Manitoba trials in Canada

Other trials for the same condition